Commentary on Cardiome is splattered in various places on SI. Several good biofreaks seem to be interested in the company, and it just seems time to give it its own board (especially since the YMB is -- unsurprisingly -- a frikkin' zoo). Ordinarily, Canadian biotechs that spring from Canadian resource companies give me considerable pause. But that was about 15 years ago. There have been regulatory stumbles, and one shot on goal went wide in PII a while back. Nevertheless, their lead compound for atrial fibrillation appears to advantages over competing drugs such as a competitor from Astra Zeneca which appears dead in the water due to tox problems not seen in the CRME drug.
Since others know a lot more than I, I'll let them fill in the blanks. |
